- Home
- BZAI vs NMRA Comparison
BZAI vs NMRA Comparison
Compare BZAI & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZAI
- NMRA
- Stock Information
- Founded
- BZAI 2010
- NMRA 2019
- Country
- BZAI United States
- NMRA United States
- Employees
- BZAI N/A
- NMRA N/A
- Industry
- BZAI
- NMRA
- Sector
- BZAI
- NMRA
- Exchange
- BZAI Nasdaq
- NMRA Nasdaq
- Market Cap
- BZAI 343.8M
- NMRA 291.5M
- IPO Year
- BZAI N/A
- NMRA 2023
- Fundamental
- Price
- BZAI $4.66
- NMRA $2.61
- Analyst Decision
- BZAI Strong Buy
- NMRA Hold
- Analyst Count
- BZAI 3
- NMRA 8
- Target Price
- BZAI $8.33
- NMRA $5.83
- AVG Volume (30 Days)
- BZAI 4.3M
- NMRA 1.7M
- Earning Date
- BZAI 11-13-2025
- NMRA 11-11-2025
- Dividend Yield
- BZAI N/A
- NMRA N/A
- EPS Growth
- BZAI N/A
- NMRA N/A
- EPS
- BZAI N/A
- NMRA N/A
- Revenue
- BZAI $3,771,000.00
- NMRA N/A
- Revenue This Year
- BZAI $2,295.50
- NMRA N/A
- Revenue Next Year
- BZAI $269.04
- NMRA N/A
- P/E Ratio
- BZAI N/A
- NMRA N/A
- Revenue Growth
- BZAI 114.63
- NMRA N/A
- 52 Week Low
- BZAI $1.70
- NMRA $0.61
- 52 Week High
- BZAI $29.61
- NMRA $14.09
- Technical
- Relative Strength Index (RSI)
- BZAI 52.08
- NMRA 76.24
- Support Level
- BZAI $4.11
- NMRA $1.68
- Resistance Level
- BZAI $6.76
- NMRA $1.85
- Average True Range (ATR)
- BZAI 0.65
- NMRA 0.19
- MACD
- BZAI -0.10
- NMRA 0.06
- Stochastic Oscillator
- BZAI 20.19
- NMRA 95.64
About BZAI Blaize Holdings Inc. Common Stock
Blaize Holdings Inc provides customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.